This site is under development. For the current active site, go to bcbhub.csic.es.

Orcid Publication

Detalle de: Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy

Title Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy
Abstract

The digestion of gluten generates toxic peptides, among which a highly immunogenic proline-rich 33-mer from wheat α-gliadin, that trigger coeliac disease. Neprosin from the pitcher plant is a reported prolyl endopeptidase. Here, we produce recombinant neprosin and its mutants, and find that full-length neprosin is a zymogen, which is self-activated at gastric pH by the release of an all-β pro-domain via a pH-switch mechanism featuring a lysine plug. The catalytic domain is an atypical 7+8-stranded β-sandwich with an extended active-site cleft containing an unprecedented pair of catalytic glutamates. Neprosin efficiently degrades both gliadin and the 33-mer in vitro under gastric conditions and is reversibly inactivated at pH > 5. Moreover, co-administration of gliadin and the neprosin zymogen at the ratio 500:1 reduces the abundance of the 33-mer in the small intestine of mice by up to 90%. Neprosin therefore founds a family of eukaryotic glutamate endopeptidases that fulfils requisites for a therapeutic glutenase.

Apa Reference del Amo-Maestro, L., Mendes, S. R., Rodríguez-Banqueri, A., Garzon-Flores, L., Girbal, M., Rodríguez-Lagunas, M. J., Guevara, T., Franch, À., Pérez-Cano, F. J., Eckhard, U., & Gomis-Rüth, F. X. (2022). Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy. Nature Communications, 13(1). 10.1038/s41467-022-32215-1
Doi 10.1038/s41467-022-32215-1
Publication Date 1 Aug 2022
Publication Type Article
Researcher Ulrich Eckhard
Ontology Mutation Analysis and design
Research Groups Synthetic Structural Biology
Tools

Suggest changes

Publications are synced automatically from ORCID, so they can't be edited here directly. Spotted something wrong? Let us know below and we'll take care of it.

← Return to Home